ActX Partners with athenahealth's 'More Disruption Please' Program to Bring Integrated Genomic Decision Support into Medical Care

SEATTLE, Oct. 13, 2016 /PRNewswire/ -- ActX, a provider of genomic decision support, today announced a partnership with athenahealth, Inc. through athenahealth's "More Disruption Please" (MDP) program, making ActX part of the athenahealth® Marketplace offerings. Together, the companies will work to link athenahealth's growing network of more than 75,000 health care providers via athenaClinicals with the capabilities of ActX to efficiently incorporate genomic decision support into existing workflow.

Logo - http://photos.prnewswire.com/prnh/20161012/428001LOGO
Logo - http://photos.prnewswire.com/prnh/20161012/428002LOGO

"ActX delivers a valuable service for healthcare providers interested in precision medicine," said Andrew Ury, MD, Founder and CEO of ActX. "In keeping with athenahealth's legacy of innovation, we are proud to make genomics a practical part of everyday medical care by incorporating it into the physician's normal workflow. The ActX Service automatically checks each prescription as it is written, and alerts the prescriber if there are potential adverse drug reactions, efficacy or dosing issues based on the patient's genetics. Physicians also are alerted about serious non-medication patient genetic risks."

athenahealth is a network-enabled services company with a vision to build an information backbone to help make health care work as it should. This relationship with athenahealth will allow ActX to spread awareness of athenahealth's services to healthcare providers interested in personalized medicine.

To learn more about athenahealth's MDP program and partnership opportunities please visit www.athenahealth.com/disruption.

About ActX
Founded in 2012, ActX helps physicians make better decisions about medical treatment, using a patient's genetic information to guide therapy. Integrated into a physician's normal software tools (the electronic medical record) and workflow, ActX analyzes the patient's genetic information in real time and alerts physicians about drug-genome interactions, actionable hereditary risks and carrier status. For more information about ActX and taking the next step towards precision medicine, visit us at www.actx.com, contact us at [email protected] or call (888) 998-2289.

Contact Info

Ashley Laabs | Marketing Communications

ActX, Inc.

Email

(888) 998 2289

SOURCE ActX, Inc.

Related Links

http://www.actx.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED